Avantor, Inc. (NYSE:AVTR) Shares Sold by Tredje AP fonden

Tredje AP fonden lowered its holdings in Avantor, Inc. (NYSE:AVTR - Free Report) by 50.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,677 shares of the company's stock after selling 52,677 shares during the period. Tredje AP fonden's holdings in Avantor were worth $1,110,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in AVTR. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock valued at $26,000 after purchasing an additional 625 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock worth $34,000 after buying an additional 830 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Avantor by 76.7% during the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company's stock worth $52,000 after buying an additional 1,067 shares during the last quarter. UMB Bank n.a. raised its position in Avantor by 56.3% in the 4th quarter. UMB Bank n.a. now owns 2,981 shares of the company's stock valued at $63,000 after purchasing an additional 1,074 shares during the last quarter. Finally, AlphaQuest LLC purchased a new stake in Avantor in the 4th quarter valued at $65,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Avantor Trading Down 1.9 %

Shares of AVTR stock traded down $0.33 during trading hours on Wednesday, hitting $16.68. 5,614,688 shares of the company were exchanged, compared to its average volume of 6,252,910. The firm has a fifty day moving average of $19.31 and a 200 day moving average of $21.88. The firm has a market cap of $11.36 billion, a PE ratio of 16.04, a PEG ratio of 1.55 and a beta of 1.30. Avantor, Inc. has a 1 year low of $15.37 and a 1 year high of $28.00. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54.

Remove Ads

Avantor (NYSE:AVTR - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same quarter in the prior year, the firm posted $0.22 earnings per share. Analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current year.

Insider Buying and Selling

In other Avantor news, EVP James Bramwell sold 3,758 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total value of $65,877.74. Following the completion of the sale, the executive vice president now owns 87,379 shares of the company's stock, valued at $1,531,753.87. This trade represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Steven W. Eck sold 4,907 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total transaction of $86,019.71. Following the completion of the sale, the chief accounting officer now directly owns 40,604 shares of the company's stock, valued at $711,788.12. This trade represents a 10.78 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

AVTR has been the subject of several research reports. UBS Group reiterated a "neutral" rating and issued a $25.00 price target (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Morgan Stanley lowered their price target on shares of Avantor from $27.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Barclays lowered their price target on shares of Avantor from $26.00 to $23.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Raymond James reissued an "outperform" rating and issued a $24.00 price objective (down from $26.00) on shares of Avantor in a research note on Monday, February 10th. Finally, Wells Fargo & Company lowered their price objective on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.